StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC)

Equities researchers at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Mizuho lowered their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. HC Wainwright restated a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a research report on Friday, November 8th. Finally, Barclays lowered their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, December 23rd. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Trading Up 1.0 %

Shares of NASDAQ:RVNC opened at $3.09 on Friday. The firm has a market capitalization of $322.57 million, a PE ratio of -1.60 and a beta of 0.86. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $8.98. The business’s 50 day moving average is $3.91 and its 200-day moving average is $4.48.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. On average, sell-side analysts predict that Revance Therapeutics will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Revance Therapeutics

Several institutional investors have recently bought and sold shares of RVNC. LMR Partners LLP acquired a new stake in shares of Revance Therapeutics in the third quarter valued at $11,648,000. Integral Health Asset Management LLC acquired a new stake in Revance Therapeutics in the 2nd quarter valued at about $1,285,000. Oddo BHF Asset Management Sas bought a new position in shares of Revance Therapeutics in the third quarter worth about $3,763,000. Alpine Associates Management Inc. acquired a new position in shares of Revance Therapeutics during the third quarter worth approximately $21,605,000. Finally, Wellington Management Group LLP bought a new stake in shares of Revance Therapeutics during the third quarter valued at approximately $2,315,000. Institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.